AI could review data sets to assist clinical scientists ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now.

Artificial intelligence has moved from pilot projects to a central role in many life sciences strategies. What began as a set ...

While regulatory alignment remains essential, operational urgency driving companies to AI adoption is equally profound. In ...

AI-leveraged drug development has become an $18 billion industry, but companies in the sector are experiencing some hardships. Beyond efforts to convenience investors their drugs are safe and ...

Executives from Absci (NASDAQ:ABSI) used a conference presentation to emphasize the company’s focus on building ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

The session Next-Generation Drug Development Enabled by Automation, Digitalization, and AI/ML is scheduled to take place at Pittcon 2026 in San Antonio, TX, on Monday, March 9, from 8:30 am–10:40 am ...

Mayo Clinic, for its part, described the collaboration as its first strategic partnership of this scale with a global ...

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won the ...

How is AI-enabled imaging complementing, augmenting or otherwise impacting existing methods and decision-making?

Here’s how drug developers can best approach interactions with the agency following last year’s seismic changes to its leadership, workforce and policies.